X連鎖性低リン血症性くる病/骨軟化症の小児患者におけるKRN23の研究

基本情報

NCT ID

NCT03233126

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

16

治験依頼者名

Kyowa Kirin Co., Ltd.

概要

Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 administered subcutaneously once every 2 weeks in children with X-linked hypophosphatemic rickets/osteomalacia(XLH). After switching to the post-marketing study: To evaluate the safety and efficacy of KRN23, which is switched from the investigational product to the post-marketing study drug, at the approved dose and dosing regimen in subjects who continue treatment

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)